These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 16047487)

  • 1. Chronic albumin infusions to achieve diuresis in patients with ascites who are not candidates for transjugular intrahepatic portosystemic shunt (TIPS).
    Trotter J; Pieramici E; Everson GT
    Dig Dis Sci; 2005 Jul; 50(7):1356-60. PubMed ID: 16047487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between increased colloid osmotic pressure and the resolution of refractory ascites after transjugular intrahepatic portosystemic shunt.
    Schiano TD; Black M; Hills C; Ter H; Bellary S; Miller LS
    South Med J; 2000 Mar; 93(3):305-9. PubMed ID: 10728519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial.
    Narahara Y; Kanazawa H; Fukuda T; Matsushita Y; Harimoto H; Kidokoro H; Katakura T; Atsukawa M; Taki Y; Kimura Y; Nakatsuka K; Sakamoto C
    J Gastroenterol; 2011 Jan; 46(1):78-85. PubMed ID: 20632194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Transjugular intrahepatic portosystemic shunt for the treatment of refractory ascites].
    Kanazawa H; Osada Y; Yoshimoto H; Narahara Y; Mamiya Y; Saitoh H; Matusaka S; Tada N; Kobayashi M; Kawamata H; Kumazaki T
    Nihon Shokakibyo Gakkai Zasshi; 1998 Mar; 95(3):221-9. PubMed ID: 9558878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term clinical outcome of patients with cirrhosis and refractory ascites treated with transjugular intrahepatic portosystemic shunt insertion.
    Tan HK; James PD; Sniderman KW; Wong F
    J Gastroenterol Hepatol; 2015 Feb; 30(2):389-95. PubMed ID: 25168607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TIPS for refractory ascites: a 6-year single-center experience with expanded polytetrafluoroethylene-covered stent-grafts.
    Bercu ZL; Fischman AM; Kim E; Nowakowski FS; Patel RS; Schiano TD; Chang CY; Lookstein RA
    AJR Am J Roentgenol; 2015 Mar; 204(3):654-61. PubMed ID: 25714299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ePTFE-TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis.
    Bucsics T; Hoffman S; Grünberger J; Schoder M; Matzek W; Stadlmann A; Mandorfer M; Schwabl P; Ferlitsch A; Peck-Radosavljevic M; Trauner M; Karner J; Karnel F; Reiberger T
    Liver Int; 2018 Jun; 38(6):1036-1044. PubMed ID: 29091351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
    Testino G; Ferro C; Sumberaz A; Messa P; Morelli N; Guadagni B; Ardizzone G; Valente U
    Hepatogastroenterology; 2003; 50(54):1753-5. PubMed ID: 14696397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transjugular intrahepatic portosystemic shunt placement for refractory ascites: a single-centre experience.
    Lodato F; Berzigotti A; Lisotti A; Azzaroli F; Mosconi C; Giampalma E; Renzulli M; Cappelli A; Buonfiglioli F; Calvanese C; Zoli M; Golfieri R; Mazzella G
    Scand J Gastroenterol; 2012 Dec; 47(12):1494-500. PubMed ID: 22958120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites.
    Bureau C; Thabut D; Oberti F; Dharancy S; Carbonell N; Bouvier A; Mathurin P; Otal P; Cabarrou P; Péron JM; Vinel JP
    Gastroenterology; 2017 Jan; 152(1):157-163. PubMed ID: 27663604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary aquaporin-2 excretion before and after transjugular intrahepatic portosystemic shunt insertion for refractory ascites.
    Geilswijk M; Thomsen KL; Pedersen EB; Vilstrup H; Grønbæk H
    Scand J Gastroenterol; 2015 Apr; 50(4):454-61. PubMed ID: 25637473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Covered stents are better than uncovered stents for transjugular intrahepatic portosystemic shunts in cirrhotic patients with refractory ascites: a retrospective cohort study.
    Maleux G; Perez-Gutierrez NA; Evrard S; Mroue A; Le Moine O; Laleman W; Nevens F
    Acta Gastroenterol Belg; 2010; 73(3):336-41. PubMed ID: 21086935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Portal decompression by transjugular intrahepatic portosystemic shunt and changes in serum-ascites albumin gradient.
    Younossi ZM; McHutchison JG; Broussard C; Cloutier D; Sedghi-Vaziri A
    J Clin Gastroenterol; 1998 Sep; 27(2):149-51. PubMed ID: 9754778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Albumin-bilirubin grade versus MELD score for predicting survival after transjugular intrahepatic portosystemic shunt (TIPS) creation.
    Ronald J; Wang Q; Choi SS; Suhocki PV; Hall MD; Smith TP; Kim CY
    Diagn Interv Imaging; 2018 Mar; 99(3):163-168. PubMed ID: 29154015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis.
    Ginès P; Uriz J; Calahorra B; Garcia-Tsao G; Kamath PS; Del Arbol LR; Planas R; Bosch J; Arroyo V; Rodés J
    Gastroenterology; 2002 Dec; 123(6):1839-47. PubMed ID: 12454841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of refractory ascites using transjugular intrahepatic portosystemic shunt (TIPS): a caution.
    Martinet JP; Fenyves D; Legault L; Roy L; Dufresne MP; Spahr L; Lafortune M; Pomier-Layrargues G
    Dig Dis Sci; 1997 Jan; 42(1):161-6. PubMed ID: 9009133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in long-term survival after transjugular intrahepatic portosystemic shunt for refractory ascites and variceal bleed.
    Membreno F; Baez AL; Pandula R; Walser E; Lau DT
    J Gastroenterol Hepatol; 2005 Mar; 20(3):474-81. PubMed ID: 15740494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transjugular intrahepatic portosystemic shunts in liver transplant recipients for management of refractory ascites: clinical outcome.
    Saad WE; Darwish WM; Davies MG; Waldman DL
    J Vasc Interv Radiol; 2010 Feb; 21(2):218-23. PubMed ID: 20123207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension.
    Colombato L
    J Clin Gastroenterol; 2007; 41 Suppl 3():S344-51. PubMed ID: 17975487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
    Wong F; Pantea L; Sniderman K
    Hepatology; 2004 Jul; 40(1):55-64. PubMed ID: 15239086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.